Avidity Biosciences

General Information


We are pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. We utilize our proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. We are initially focused on muscle diseases to demonstrate the capabilities of our AOCs, and our muscle franchise consists of five programs. 

Employees: 38
Founded: 2020
Contact Information
Address 10975 N. Torrey Pines Road, Suite 150, La Jolla, CA 92037, US
Phone Number 858-401-7900
Web Address http://www.aviditybiosciences.com
View Prospectus: Avidity Biosciences
Financial Information
Market Cap $636.3mil
Revenues $3.7 mil (last 12 months)
Net Income $-28.3 mil (last 12 months)
IPO Profile
Symbol RNA
Exchange NASDAQ
Shares (millions): 14.4
Price range $18.00 - $18.00
Est. $ Volume $259.2 mil
Manager / Joint Managers Cowen and Company/ SVB Leerink/ Credit Suisse/ Wells Fargo Securities
CO-Managers -
Expected To Trade: 6/12/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change